Source comparison
Dosing Protocols Based on Forums vs Published Literature
The most common TB-500 myth that costs researchers money: extrapolating human-equivalent doses from anecdotal reports rather than scaling from peer-reviewed animal studies using allometric conversion factors. Published research in the Journal of Cardiovascular
This comparison does not assign a generated winner or score.
- The most common TB-500 myth that costs researchers money: extrapolating human-equivalent doses from anecdotal reports rather than scaling from peer-reviewed animal studies using allometric conversion factors. Published research in the Journal of Cardiovascular Pharmacology used TB-500 at 6 mg/kg in rodent models to demonstrate angiogenic effects. Translating that to a 70kg human using FDA-standard allometric scaling (dividing by 6.2) yields approximately 67mg per administration, not the 2–5mg commonly referenced in non-scientific forums.
- Dosing myths compound when researchers assume linear dose-response relationships. Thymosin beta-4 operates through G-protein coupled receptor pathways (specifically formyl peptide receptors) that exhibit saturation kinetics. Meaning doses above the receptor saturation threshold don't produce proportionally greater effects, they just waste compound. A study published in Wound Repair and Regeneration found that TB-500 concentrations above 10 mg/kg in murine models showed no additional benefit over 6 mg/kg dosing, but cost 66% more per experimental run.
- Researchers who purchase MK 677 for growth hormone research apply this same principle: the effective dose is determined by receptor kinetics and clearance rates, not by amateur speculation. The honest answer: if your TB-500 protocol wasn't derived from published pharmacokinetic data, you're spending money to generate noise, not signal.